Janssen has announced results from a post-hoc analysis which shows that treatment with INVOKANA®‚ (canagliflozin) reduces both HbA1c and body weight in most patients with type 2 diabetes mellitus who are also receiving metformin.
The data showed that at 52 weeks, canagliflozin provided reductions in both HbA1c and body weight in more patients with type 2 diabetes mellitus as an add-on to metformin, when compared with sitagliptin 100mg or glimepiride.
The data was published at the 50th European Association for the Study of Diabetes (EASD) in Vienna last week.
The analysis used data from two separate randomised, double-blind, active-controlled Phase III studies of canagliflozin 100mg and 300mg versus either sitagliptin 100mg or glimepiride and involved 2,734 patients.
Results showed a greater proportion of patients had reductions in both HbA1c and body weight with canagliflozin 100mg and 300mg compared with sitagliptin 100 mg, or glimepiride. Canagliflozin 300mg was associated with greatest reductions in HbA1c and body weight when compared to sitagliptin 100mg and glimepiride.
In both studies, changes in HbA1c and body weight were measured.
In the second study comparing canagliflozin to glimepiride, mean HbA1c changes from baseline were -0.82%, -0.93%, and -0.81%, and mean body weight (BW) changes from baseline were -4.2%, -4.7%, and 1.0% with canagliflozin 100mg and 300mg and glimepiride, respectively. Of the patients that had a decrease in HbA1c, more saw either no change on an increase in BW with sitagliptin or glimepiride versus canagliflozin 100mg and 300mg in both studies.
Dr Shana Traina, Director, Patient Reported Outcomes, Janssen R&D US, said: “It is important to consider the patient experience when collaborating with individuals on weight and disease management strategies.”